<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239626</url>
  </required_header>
  <id_info>
    <org_study_id>SMC 2017-03-092-002</org_study_id>
    <nct_id>NCT03239626</nct_id>
  </id_info>
  <brief_title>Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer</brief_title>
  <official_title>Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer: A Prospective Exploratory Trial (POHIM_RT Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the acute toxicities, late toxicities, and treatment results when the early
      cervical cancer patients are treated by hypofractionated intensity-modulated radiotherapy
      (2.5 Gy X 16 fractions, once a day) after radical hysterectomy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Anticipated">April 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>One group for hypofractionaed IMRT for adjvuant cervical cancer patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>acute toxicities according to CTCAE v4.0</measure>
    <time_frame>3 months</time_frame>
    <description>evaluation of acute toxicities within 3months after radiotherapy according to CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>late toxicities according to CTCAE v4.0</measure>
    <time_frame>5-years</time_frame>
    <description>evaluation of late toxicities every year after 3months after radiotherapy according to CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>5-years</time_frame>
    <description>progression free survival rate after the time of surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cervix Cancer</condition>
  <condition>Radiotherapy, Adjuvant</condition>
  <condition>Radiotherapy, Intensity-Modulated</condition>
  <condition>Hypofractionated Dose</condition>
  <arm_group>
    <arm_group_label>POHIM-RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adjuvant hypofractionated IMRT for cervical cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>POHIM-RT</intervention_name>
    <description>postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)</description>
    <arm_group_label>POHIM-RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed cervical cancer

          -  radical hysterectomy and pelvic lymph node dissection was done

          -  histologically indicated adjuvant radiotherapy ( more than one as below)

               1. tumor size ≥4 cm

               2. positive lymphovascular invasion

               3. more than half stromal invasion depth

          -  ECOG performance status 0 or 1

          -  Bone marrow function: granulocyte ≥1.0 x 1000/µl, platelet ≥30 x 1000/µl, hemoglobin
             ≥10 g/dl

        Exclusion Criteria:

          -  positive pelvic lymph node metastasis

          -  positive distant metastasis (including retroperitoneal lymph node metastasis)

          -  positive tumor involvement on resection margin

          -  positive parametrial invasion

          -  previous history of pelvic radiotherapy

          -  more than 3 months after radical surgery for cervical cancer

          -  neoadjuvant chemotherapy was done

          -  previous history of other carcinoma except for thyroid cancer, skin cancer, in situ
             carcinoma on cervix
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Park, M.D.,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Won Park, M.D., Ph.D</last_name>
    <phone>+82-10-9933-2616</phone>
    <email>wonro.park@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Park, M.D.,Ph.D</last_name>
      <phone>+82-2-3410-2616</phone>
      <email>wonro.park@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

